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Abstract
BACKGROUND: Preliminary clinical evaluation of 99mTc-EDDA/HYNIC-Met14-Exendin-4 showed that the complex offers new 
diagnostic possibilities for insulinoma and MTC. Exendin-4 contains methionine at position 14 in the amino acid chain, which 
may be oxidized to methionine sulfoxide and, from the pharmaceutical point of view, the oxidized moiety becomes an undesired 
impurity in the final radioactive preparation. Therefore, the aim of this study was to investigate the influence of commonly used 
methods to eliminate the effect of methionine oxidation in peptides, i.e. the replacement of methionine by norleucine (Nle) and 
the addition of L-methionine, on the in vitro stability and the biodistribution. 
MATERIAL AND METHODS: 99mTc-EDDA/HYNIC-Met14-Exendin-4, 99mTc-EDDA/HYNIC-Nle14-Exendin-4, 99mTc-EDDA/HYNIC-Met14-Ex-
endin-4 with the addition of L-methionine and an oxidized form of Exendin-4, i.e. 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 were 
compared in vivo with 68Ga-NODAGA-Nle14-Exendin-4 in normal Wistar rats. The stability and lipophilicity were determined in vitro. 
RESULTS: Biodistribution studies confirmed the specific uptake of all tested complexes in the GLP-1 positive organs: 
lungs, pancreas and stomach. The uptake of 99mTc-EDDA/HYNIC-Met14-Exendin-4 with the addition of L-methionine and 
for 68Ga-NODAGA-Nle14-Exendin-4 at 1h p.i. was around 2-fold higher than that of 99mTc-EDDA/HYNIC-Met14-Exendin-4 and 
99mTc-EDDA/HYNIC-Nle14-Exendin-4. 
CONCLUSION: Although the substitution of methionine by norleucine in the HYNIC-Exendin-4 did not result in improved bio-
distribution, the use of L-methionine, as the excipient that inhibits the oxidation of methionine in the peptide chain resulted in 
higher lung/blood and stomach/blood uptake ratios. Our results confirmed that methionine at position 14 of amino acid chain 
of Exendin-4 plays an important role in the interaction with GLP-1 receptor positive tissue.
KEY words: 68Ga-NODAGA-Nle14-Exendin-4, 99mTc-EDDA/HYNIC-Met14-Exendin-4, 99mTc-EDDA/HYNIC-Nle14-Exendin-4, 
L-methionine, GLP-1, methionine sulfoxide
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Introduction
Insulinomas are rare endocrine tumors. Detection of insuli-
noma is still very difficult using standard diagnostic techniques. 
Surgery can be performed only if this small tumor is well localized. 
The sensitivity of somatostatin receptor scintigraphy (SRS) is only 
40–60% due to relatively low incidence of somatostatin subtype 
receptor sstr2 and sstr5 expression in insulinomas [1]. Importantly, 
in insulinomas the glucagon like peptide-1 receptors (GLP-1R) 
are expressed with high incidence and high density, twice that 
of sstr2 [2, 3]. The natural agonist of GLP-1R is a 30 amino acid 
hormone that is rapidly degraded by dipeptidyl peptidase IV [4].
The more stable agonists are Exendin-4 and Exendin-3. Conse-
quently, GLP-1 receptor-avid radioligands have been developed and 
evaluated [5–8]. In particular, the preclinical animal studies have 
shown the ability of [Lys40(Ahx [6-aminohexanoic acid]-DTPA-111In)
NH2]-Exendin-4 to successfully localize small insulinomas in the 
Rip1Tag2 mouse tumor model [8] and presented the potential 
for GLP-1 targeting as therapeutic approach [9]. This new tracer 
was efficient in localizing the pancreatic tumors and insulinomas, 
which had previously not been identified using conventional 
methods [10, 11]. Furthermore, the new Exendin-4 analogs were 
developed aimed at overcoming the drawbacks of 111In-imaging. 
Namely, these were [Lys40(Ahx-hydrazinonicotinamide [HYNIC]-
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99mTc/ethylenediaminediacetic acid [EDDA]NH2]-Exendin-4 for 
SPECT and [Lys40(Ahx-DOTA-68Ga)NH2]-Exendin-4 for PET/CT. The 
preclinical evaluation of these tracers and Lys40(Ahx-DTPA-111In)
NH2]-Exendin-4 in the Rip1Tag2 mouse model of pancreatic 
b-cell carcinogenesis revealed that all three of them showed high 
tumor-to-background ratio, resulting in the visualization of tumors. 
Very high tumor uptake of [Lys40(Ahx-DOTA-68Ga)NH2]-Exendin-4 
at the level 205 ± 59 percentage injected activity per gram tissue 
at 4h p.i. was observed, while for the other two radiopeptides it 
was significantly lower. However, a lower tumor and organ uptake 
of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-Exendin-4 did not result in 
the inferior tumor-to-organ ratio or reduced image quality [12]. 
This prompted us to further develop this tracer into the clinically suit-
able formulation. Moreover, in our experience, the diagnostic utility 
of a GLP-1receptor agonist, [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]- 
-Exendin-4 obtained from the developed dry kit, has been proven 
in a small group of patients with insulinoma [13] and MTC [14]. 
The peptide Exendin-4 contains methionine at position 14 in the 
amino acid chain, which may be oxidized and, from the pharma-
ceutical point of view, the oxidized moiety becomes an undesired 
impurity in the final radioactive preparation. In case of other bio-
molecules it has been shown that oxidation of methionine to me-
thionine sulfoxide causes their lower bioactivity [15, 16]. Oxidation 
of methionine present in the amino acid sequence of peptides can 
have significant influence on the receptor binding affinities. Notably, 
oxidation of methionine in gastrin analogs dramatically reduces the 
affinity for CCK-2 receptors [17]. Various approaches were applied 
to prevent the oxidation of methionine during radiolabeling of pep-
tides, such as addition of antioxidants, including selenomethionine 
and L-methionine as well as gentisic acid and ascorbic acid [17, 18]. 
The other option is to replace the methionine with another amino 
acid, which would not be prone to oxidation. Norleucine is the 
most commonly used substitute due to its chemical similarity 
to methionine. The replacement of methionine by norleucine in 
minigastrin analogs did not significantly affect binding affinities to 
CCK-2R receptors [19]. 
Although the development of several radiolabeled Exendin-4 
analogs has been reported, the GLP-1 receptor affinities of these 
analogs, assessed in various cell lines do not differ significantly 
[8, 12, 19–22]. However, so far, there is no published data on the 
GLP-1 receptor affinity of the oxidized form of Exendin-4. Therefore, 
the aim of this work was to investigate the influence of commonly 
used methods to eliminate the effect of methionine oxidation in pep-
tides, i.e. the replacement of methionine by norleucine (Nle) and the 
addition of L-methionine to the radiolabeling mixture on the in vitro 
stability and the biodistribution in normal rats. In this study we char-
acterized and compared the following complexes: 68Ga-NODAGA- 
-Nle14-Exendin-4, 99mTc-EDDA/HYNIC-Met14-Exendin-4, 99mTc-EDDA/ 
/HYNIC-Nle14-Exendin-4, 99mTc-EDDA/HYNIC-Met14-Exendin-4 with 
the addition of L-methionine and an oxidized form of Exendin-4, i.e. 
99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4. 
Material and methods
Reagents
Chemicals were purchased from Aldrich-Sigma Chemi-
cals Co (Poznan, Poland). Met14, Lys40(Ahx-HYNIC)-Exendin-4 
(HYNIC-Met14-Exendin-4), Nle14, Lys40(Ahx-HYNIC)-Exendin-4 
(HYNIC-Nle14-Exendin-4), Nle14, Lys40(Ahx-NODAGA)-Exendin-4 
(NODAGA-Nle14-Exendin-4) were custom-synthesized by piCHEM 
(Graz, Austria). 99mTcO4
- was obtained from the domestic 99Mo/99mTc 
generator (Radioisotope Centre POLATOM, Poland). 68GaCl3 
was obtained from 68Ge/68Ga generator (IThemba Labs, Republic 
of South Africa). ITLC SG was purchased from Agilent Technolo-
gies (United States). 
Quality control
The radiochemical purity was determined by HPLC and TLC 
chromatography. HPLC analysis was performed on a Luna 5 µm 
C18(2) 100A, 4.6 x 250 mm column (Phenomenex) using a Varian 
system equipped with a dual wave length spectrophotometer set 
and on-line radioactivity detector connected in series. The chro-
matographic conditions were as follows: flow rate 1 ml/min, gradi-
ent elution: 0 min — 10% B, 10 min — 10% B, 22 min — 50% B, 
25 min — 10% B, 30 min — 10% B, mobile phase A: 0.1% TFA in 
H2O, B: 0.1% TFA in ACN. The radiochemical purity was expressed 
as the percentage of the peak corresponding to labeled peptide 
in the total activity in the radiochromatogram. The injected activity 
on the HPLC-column was ca. 5 MBq.
Instant TLC (ITLC) was performed using silica gel (iTLC 
SG-glass microfiber chromatography plates impregnated with 
silica gel, 2 cm x 10 cm) with 2-Butanone used to determine the 
amount of free 99mTcO4
- (Rf = 1), ACN: H2O (1: 1, v: v) to determine 
99mTc-colloid (Rf = 0) and 0.1 M citrate buffer pH 5.0 to determine 
the 99mTc-Tricine and 99mTc-EDDA (Rf = 1).
The 0.1 M citrate buffer pH 5.0 was used to determine the 
free 68GaCl3 (Rf = 0.8–1.0) and 5M ammonium acetate : methanol 
(1: 1, v: v) to determine 68Ga-colloid (Rf = 0–0.2). An undiluted 
sample drop of about 5 µl of radiolabeled Exendin-4 was placed 
on the start line (1 cm from bottom) and the solvent was allowed 
to migrate up to 0.5 cm from the top of the plate. The distribution 
of radioactivity on radiochromatograms was determined using 
Cyclone®Plus (PerkinElmer).
Radiolabeling 
The “wet” 99mTc-labeling of HYNIC-Met14-Exendin-4 and 
HYNIC-Nle14-Exendin-4 was performed to optimize the quantity 
and concentration of reagents, temperature and reaction time 
which were then used to develop the dry kit formulation. One-vial 
dry kit was prepared with the following composition: 30 µg of 
HYNIC-Met14-Exendin-4 or HYNIC Nle14-Exendin-4, 40 µg of SnCl2 x 
2H2O, 50 mg of Tricine [N-[Tris(hydroxymethyl)-methyl-glycine] and 
5 mg of EDDA (Ethylenediamine-N,N’-diacetic acid). Radiolabel-
ing was performed using the eluate from the 99Mo/99mTc generator 
eluted within 24h previously.
One-vial kit formulation for the preparation of 99mTc-EDDA/HYNIC- 
-Met14-Exendin-4 with the addition of L-methionine contained: 30 µg 
of HYNIC-Met14-Exendin-4, 40 µg of SnCl2 x 2H2O, 50 mg of Tricine, 
30 mg L-methionine and 5 mg of EDDA.
For 99mTc labeling, the kit vial was reconstituted with 1.5 ml of elu-
ate (0.7GBq–1.5GBq radioactivity), followed by 10 min incubation 
at 100°C in a dry block heater. After cooling to room temperature 
the radiochemical purity of labeled peptide was controlled by TLC 
and HPLC.
99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 was prepared by oxida-
tion of previously prepared 99mTc-EDDA/HYNIC-Met14-Exendin-4. To 
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a 6.58 nM solution of 99mTc-EDDA/HYNIC-Met14-Exendin-4 100 µl of 
30% H2O2 were added and the mixture was incubated for 15 min at 
room temperature. Purification was performed using a solid phase 
extraction column (Oasis® HLB 1cc 30mg extraction cartridges). 
The unbound technetium-99m was eluted with 5 ml of water and 
99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 was eluted with 1 ml of etha-
nol. Its identity and radiochemical purity were confirmed by HPLC.
For 68Ga labeling, 30 µg of NODAGA-Nle14-Exendin-4 in 400 µl 
of 2.5MHEPES[4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic 
acid] was incubated with 68GaCl3 (0.2 GBq–0.5 GBq radioactivity) 
for 10 min at 1000C. pH of the solution was 3.8–4.0.
2.4. In vitro stability studies
The stability of 68Ga-NODAGA-Nle14-Exendin-4, 99mTc-EDDA/ 
/HYNIC-Met14-Exendin-4, 99mTc-EDDA/HYNIC-Nle14-Exendin-4 and 
99mTc-EDDA/HYNIC-Met14-Exendin-4 with the addition of L-methio-
nine were performed by incubation of 200 µL of radiolabeled peptide 
in 1000 µL of 0.9% NaCl. The stability was evaluated by reversed 
phase-HPLC at different time points: 1h, 2h, 4h, and 6h.
Octanol/water partition coefficient
The lipophilicity of the 68Ga-NODAGA-Nle14-Exendin-4, 99mTc-EDDA/ 
/HYNIC-Met14-Exendin-4, 99mTc-EDDA/HYNIC-Nle14-Exendin-4, 
99mTc-EDDA/HYNIC-Met14-Exendin-4 with the addition of L-methio-
nine and 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 was determined 
using the octanol/water partition coefficients. To 0.1 ml of radiola-
beled Exendin-4 preparation, 0.4 ml of 1-octanol and 0.3 ml of 
water were added. After being vigorously mixed for 1 min and gently 
mixed for an additional 10 min, the two phases were separated by 
centrifugation at 4000 g for 10 min. The aliquots were counted for 
radioactivity and partition coefficient (P) were calculated as the 
logarithm of the radioactivity ratio in the octanol and water phases. 
Biodistribution studies
The animal experiments were approved by The 4th Local 
Animal Ethics Committee in Warsaw (the authorization number 
78/2011 and 18/2015), and were carried out in accordance with the 
national legislation regarding laboratory animals protection and the 
principles of good laboratory practice. The animals used in this trial 
were permitted to food and water ad libitum.
For biodistribution experiments 0.15 µg (ca. 32 pM) aliquots of 
each radiolabeled Exendin-4 preparation were injected, i.v. (tail vein) 
to normal Wistar rats (male, n = 5 per group) in a volume of 0.2 ml. 
For receptor blocking, the respective groups were co-injected with 
100-fold excess of respective non-labeled compound. During the 
experiments, the animals were housed in metabolic cages. At 1h 
post-injection (p.i.) the animals were sacrificed under anesthesia 
with 3% isoflurane. Samples of blood and selected tissues were 
collected, weighed and then measured for radioactivity content. The 
radioactivity in these samples was determined using g-counter and 
calculated as a percentage of injected dose (%ID) or as percentage 
of injected dose per gram (%ID/g). 
Results
Radiolabeling and stability study
The labeling yield of 68Ga-NODAGA-Nle14-Exendin-4 was 96% at 
a specific activity of 63 GBq/µmol. The labeling yield of 99mTc-EDDA/ 
/HYNIC-Met14-Exendin-4, 99mTc-EDDA/HYNIC-Nle14-Exendin-4, 
99mTc-EDDA/HYNIC-Met14-Exendin-4 with the addition of L-me-
thionine and 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 were 94%, 
97% and 96%, 94%, respectively, at a specific activity of ca. 
100 GBq/µmol for each preparation.
Despite the fact that the prepared dry kits were stored at 
the fridge temperature (5°C ± 3°C) after a couple of months the 
contribution of 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 impurity 
was observed in HPLC radiochromatograms as an additional peak 
located in close proximity to the radiolabeled 99mTc-EDDA/HYNIC- 
-Met14-Exendin-4 (Figure 1). The increase of this impurity was also 
observed with the time of storage of the radiolabeled preparation. 
To identify the individual impurities in the HPLC, the components of 
the labeling mixture, EDDA and tricine were labeled with 99mTc 
and the 99mTc-EDDA/HYNIC-Met14-Exendin-4 was incubated with 
30% H2O2 to increase oxidation. The retention times of observed 
impurities were in agreement with a retention time of specified 
standard as shown in Table 1. In order to reduce the oxidation 
of methionine in HYNIC-Met14-Exendin-4, various quantities of 
L-methionine were added to the dry kit of HYNIC-Met14-Exendin-4. 
The most pronounced effect of reducing the content of 99mTc-EDDA/ 
/HYNIC-Met14(ox)-Exendin-4 to around 2.5% was obtained after 
Figure 1. HPLC-radiochromatogram 99mTc-EDDA/HYNIC-Met14-Exendin-4
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addition of 30 mg of L-methionine and was not further improved 
with higher mass of L-methionine, therefore 30 mg was used in 
the biological assays. The effect of L-methionine on radiochemical 
purity is presented in Table 2.
Lipophilicity
The Log(P) values for 68Ga-NODAGA-Nle14-Exendin-4, 
99mTc-EDDA/HYNIC-Met14-Exendin-4, 99mTc-EDDA/HYNIC-Nle14-Ex-
endin-4, 99mTc-EDDA/HYNIC-Met14-Exendin-4 with L-methionine 
and 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 were: –1.92 ± 0.01, 
–2.33 ± 0.004, –1.95 ± 0.007, –2.17 ± 0.005 and –2.79 ± 0.05, 
respectively. These results indicate that all compounds are hydro-
philic, although the oxidized Exendin-4 was the most hydrophilic. 
Biodistribution studies
The biodistribution of 68Ga-NODAGA-Nle14-Exendin-4, 99mTc-EDDA/ 
/HYNIC-Met14-Exendin-4, 99mTc-EDDA/HYNIC-Nle14-Exendin-4, 
99mTc-EDDA/HYNIC-Met14-Exendin-4 with L-methionine and 
99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 in Wistar rats at 1h p.i. 
is summarized in Figure 2. All tested radiopeptides showed high 
uptake of radioactivity in the GLP-1 receptor positive organs, such 
as the lungs, pancreas and stomach. This uptake was shown 
to be receptor specific, given the significant reduction of the 
uptake in the group of animals receiving an excess of respective 
“cold” Exendin-4 compound (15 µg) (Figure 3). Out of the five 
compared preparations, the 68Ga-NODAGA-Nle14-Exendin-4 and 
99mTc-EDDA/HYNIC-Met14-Exendin-4 with L-methionine showed 
the highest and comparable uptake in the GLP-1 receptor rich 
organs (lungs: 24.81 ± 0.95% ID/g and 19.08 ± 2.75% ID/g, 
pancreas: 0.32 ± 0.04% ID/g and 0.22 ± 0.06% ID/g, stomach: 
0.53 ± 0.16% ID/g and 1.23 ± 0.17% ID/g, respectively). Two other 
analogs, 99mTc-EDDA/HYNIC-Met14-Exendin-4 and 99mTc-EDDA/ 
/HYNIC-Nle14-Exendin-4 showed similar uptake in GLP-1 positive 
organs; however, it was more than twice lower than for the first 
Table 1. Identification of impurities in 99mTc-EDDA/HYNIC-Met14- 
-Exendin-4
No. Retention time [min] Substance
1. 2.68 99mTc-EDDA
2. 3.05 99mTc-Tricine
3. 4.35 99mTcO4
-
4. 18.87 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4
5. 19.17 99mTc-EDDA/HYNIC-Met14-Exendin-4
6. 19.57 Unidentified
Table 2. The influence of L-methionine on the radiochemical purity of 99mTc-EDDA/HYNIC-Met14-Exendin-4
L-Methionine [mg] 0 5 10 20 30 40
Radiochemical purity:  
99mTc-EDDA/HYNIC-Met14-Exendin-4 (%) 90.26 ± 0.2 91.63 ± 0.5 92.18 ± 0.9 94.40 ± 0.7 96.17 ± 0.5 96.46 ± 1.1
99m
Tc-EDDA/HYNIC-Met14(ox)-Exendin-4 (%) 9.07 ± 0.3 7.54 ± 0.6 5.69 ± 0.7 3.72 ± 0.4 2.49 ± 0.6 2.54 ± 0.9
Figure 2. Biodistribution at 1h p.i. in normal Wistar rats (n = 5) of 68Ga-
NODAGA-Nle14-Exendin-4, 99mTc-EDDA/HYNIC-Met14-Exendin-4, 99mTc-
EDDA/HYNIC-Nle14-Exendin-4, 99mTc-EDDA/HYNIC-Met14-Exendin-4 
with L-methionine and 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 (mean 
values of %ID/g ± SD; n = 5 for each compound)
Figure 3. Biodistribution at 1h p.i. in normal Wistar rats (n = 5) of 68Ga-NODAGA-Nle14-Exendin-4 (1), 99mTc-EDDA/HYNIC-Met14-Exendin-4 (2), 99mTc- 
-EDDA/HYNIC-Nle14-Exendin-4 (3), 99mTc-EDDA/HYNIC-Met14-Exendin-4 with L-methionine (4) and 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4 (5) alone 
and blocked accumulation in the positive organs by co-injection of 15 µg unlabeled Exendin-4
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two (lungs: 7.75 ± 1.41% ID/g and 8.11 ± 1.24% ID/g, pancreas: 
0.14 ± 0.02% ID/g and 0.14 ± 0.02% ID/g, stomach: 0.58 ± 0.17% 
ID/g and 1.09 ± 0.06% ID/g, respectively). It should be noticed 
that for the 99mTc-EDDA/HYNIC-Met14(ox)-Exendin-4, the uptake 
in the lungs was 3.17 ± 0.51% ID/g, in pancreas: 0.06 ± 0.01% 
ID/g, which is four times lower than for the first two and twice lower 
than for the other two preparations.The renal uptake of all tested 
radiolabeled peptides was at the level of more than 20%, similar 
for all preparations. It was not blocked by an excess of ”cold” 
Exendin-4 (data not shown), indicating that the renal uptake is not 
GLP-1 mediated.
Discussion
99mTc-EDDA/HYNIC-Met14-Exendin-4, obtained from the dry 
kit formulation, has been proven useful in SPECT imaging of in-
sulinomas and MTC [13, 14]. Therefore, the development of the 
kit formulation for EDDA/HYNIC-Met14-Exendin-4 for labeling with 
technetium-99m was an important achievement in our studies. 
However, we observed that methionine in Exendin-4 when oxidized 
during storage, what resulted in decreasing the radiochemical 
purity of the preparation after radiolabeling with 99mTc. Typically, 
the recommended limit of RCP for the 99mTc-labeled preparations, 
such as 99mTc-EDDA/HYNIC-Met14-Exendin-4 or 99mTc-EDDA/HYNIC- 
-Nle14-Exendin-4, is > 90% and the specified impurities are related 
to the radiochemical forms of 99mTc (either as free pertechnetate 
or reduced-hydrolyzed forms). The oxidized form of the peptide 
constitutes another impurity and worsens the overall radiochemi-
cal purity of the preparation. It is known from others experience 
that the application of an antioxidant such as selenomethionine, 
gentisic acid, ascorbic acid or L-methionine affects the inhibition of 
methionine oxidation in peptides [17, 23, 24]. Using this approach 
we were also able to improve the stability of HYNIC-Met14-Exendin-4 
during storage of the dry kit by addition of L-methionine as an anti-
oxidant to the dry kit formulation and also prevent the formation of 
the oxidized form in the final radioactive preparation.
Although the development of several radiolabeled Exendin-4 
analogs has been reported, the receptor affinities of these ana-
logs to certain cell lines do not differ significantly. However, so far, 
there is no published data on the GLP-1 receptor affinity of the 
oxidized form of Exendin-4. The introduction of chelator in va-
rious lysine positions gave compounds with comparable biological 
activity with the in vitro binding affinities to GLP-1R in the range of 
29 to 54 nM; however, only the lysines at positions 12 and 40 were 
suggested as preferential modification site [18]. In another study, 
both lysine residues appeared to be important for the affinity to the 
GLP-1 receptor [25]. Other modifications like e.g. blocking the SH 
group of cysteine at position 40 by the introduction of MAL link-
age did not change biological activity, but reduced accumulation 
in the kidneys [26]. 
On the other hand, it is well known, that oxidation of methionine 
causes a significant change in its biophysical properties and often 
leads to an alteration of protein functions. Methionine has a long 
and non-polar side chain, which becomes polar upon oxidation. The 
hydrophobicity index of MetO has been estimated to be similar to 
that of Asn (asparagine), as it has been found for gastrin analogs. 
Therefore, the oxidation of Met can be considered as a substitution 
of a hydrophobic for a hydrophilic amino acid and is expected to 
have pronounced structural and functional consequences. Herein 
reported results of partition coefficient confirmed that the prepara-
tion of Exendin-4 with oxidized Met14 was the most hydrophilic of all 
tested preparations, whereas the 68Ga-NODAGA-Nle14-Exendin-4 
was the most lipophilic, probably due to the highly, in relation to 
methionine, hydrophobicity of norleucine. 
These differences had impact on the biodistribution of evalu-
ated tracers in our studies. It should be noted that in all cases the 
GLP-1 receptor specific uptake was observed in the organs naturally 
overexpressing these receptors, such as the lungs, pancreas and 
stomach. This uptake could be blocked by the coinjection of the 
excess of “cold” peptide. However, as presented in Figure 3, this up-
take was the lowest for the oxidized form of Exendin-4, suggesting 
that the receptor affinity is enhanced by methionine oxidation. In our 
study 68Ga-NODAGA-Nle14-Exendin-4 served as an internal stan-
dard for comparison of specific uptake to the GLP-1R expressing 
organs since it was well characterized previously both in terms of re-
ceptor binding affinity and biodistribution and tumor visualization in 
animals [22]. High receptor affinity was reported for [natGa-NODAGA- 
-Nle14-Exendin-4], the IC50 value was 2.17 ± 0.42 nM while for 
native GLP-1 it was 1.0 ± 0.2 nM. The same authors reported the 
log (P) value for 68Ga-NODAGA-Nle14-Exendin-4 of -2.38 ± 0.037, 
confirming its hydrophilic character. 
The uptake in GLP-1 negative tissues such as liver was low 
in all 99mTc-labeled Exendin-4 formulations. Relatively high uptake 
of 68Ga-NODAGA-Nle14-Exendin-4in the liver can be explained by 
68Ga release from the chelator due to the transchelation with blood 
cells [27]. In case of 68Ga-labeled radiopeptide, the radioactive 
metabolites formed and free gallium can potentially negatively affect 
the imaging quality and increase the dose to non-target tissue. The 
low hepatic background level for 99mTc-EDDA/HYNIC-Met14-Exen-
din-4 with L-methionine is noteworthy since liver is a major site for 
potential metastasis from insulinoma. 
68Ga- and 99mTc-labeled Exendin-4 analogs are characterized 
by a very high kidney uptake [28]. In our study, the coinjection 
of an excess of “cold” Exendin-4 did not change renal uptake 
of 68Ga and 99mTc Exendin-4 analogs, indicating that it was not 
GLP-1R specific in this tissue, since other mechanisms are involved 
[29–32].Tracers for GLP-1R imaging are excreted primarily through 
the kidneys and can be partially absorbed in the proximal tubule 
cells. The radiation dose to the kidneys can cause renal toxicity, 
hence limiting their use for peptide receptor radionuclide therapy.
The rapid clearance from the blood observed for all tested 
preparations resulted in high lungs/blood uptake ratio. The high-
est ratio was 172.7 ± 29.7 for 99mTc-EDDA/HYNIC-Met14-Exendin-4 
with L-methionine (Figure 4). The high value of lungs/blood uptake 
ratio points to the great potential diagnostic for 99mTc-EDDA/HYNIC- 
-Met14-Exendin-4 with L-methionine. The value of pancreas/blood 
(1.9 ± 0.5) and stomach/blood (11.0 ± 09) uptake ratio is much 
lower; however, it was again the highest for 99mTc-EDDA/HYNIC- 
-Met14-Exendin-4 with L-methionine (Figures 5, 6). 
The observed oxidation of methionine in 99mTc-EDDA/HYNIC- 
-Met14-Exendin-4 reduced the accumulation of the radioactivity in 
the GLP-1 positive organs compared to the same peptide with ad-
dition of L-methionine. Interestingly, the replacement of methionine 
in the peptide chain of Exendin-4 by norleucine did not increase 
the accumulation of 99mTc-EDDA/HYNIC-Nle14-Exendin-4 in the 
GLP-1 rich organs, although a slight increase in receptor affinity 
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compared to the 111In-DTPA-Met14-Exendin-4 was reported for the 
68Ga-NODAGA-Nle14-Exendin-4.
Conclusion
In this work we have shown that addition of methionine to pre-
vent oxidation of 99mTc-EDDA/HYNIC-Met14-Exendin-4 allows impro-
ving the biodistribution profile of this potential radiopharmaceutical 
compared with the non-protected formulation. Another approach to 
obtain similar effect, utilizing norleucine as a replacement for me-
thionine resulted in 99mTc-EDDA/HYNIC-Nle14-Exendin-4; however, 
this peptide did not appear to present more favorable biodistribu-
tion. This might confirm that presence of methionine in the phar-
macophore of Exendin-4 is crucial for its affinity to GLP-1 receptors. 
However, this conclusion requires further verification. 
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